SynRx Therapeutics announces the presentation of its PARG inhibitor program at the 36th EORTC-NCI-AACR Symposium taking place in Barcelona, Spain, on October 25, 2024. Poly (ADP-robose) glycohydrolase (PARG) is an enzyme that cleaves ADP-ribose polymers synthesized by members of the poly (ADP-ribose) polymerase (PARP) family of enzymes. During DNA damage repair, PARG hydrolyzes poly (ADP-ribosyl)ation (PARylation) as a sequential step of PARylation to mediate the relocation of DNA damage repair machinery to recognize and repair DNA lesions. The presentation showcases a favorable and highly competitive preclinical profile of PARG inhibitor SYN608. SYN608 exhibited robust efficacy in solid tumor models with homologous recombination deficiency (HRD), base excision repair (BER) deficiency and an undisclosed biomarker. The key differentiations of SYN608 include highly potent single-agent activity, strong in vivo efficacy in PARP inhibitor resistant cancers, reduced hERG risk and a favorable safety profile. SYN608 has demonstrated Best-in-Class characteristics and holds great potential for further development. IND-enabling studies are ongoing, with plans to submit IND applications to both US FDA and China NMPA.

Presentation details:

• Title: Preclinical Candidate SYN608, A Novel PARG Inhibitor with Excellent Anti-tumor Activity
  
• Date: October 25, 2024
  
• Poster Session: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM) 
  
• Poster Number: 355